{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:05:07Z","timestamp":1793502307583,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The purpose of this study is to clarify the changes in peripheral blood eosinophil (PBE) counts and eosinophilic granulomatosis with polyangiitis (EGPA) onset in patients with asthma who were treated with dupilumab in clinical practice. Methods: The primary outcome of this study is to determine the onset of EGPA in patients whose PBE counts continued to rise within 6 months of dupilumab initiation (rising group) and in patients whose PBE counts peaked and subsequently declined within 6 months (peaked and declined group). As a secondary outcome, the incidence of developing EGPA in patients with PBE counts greater than 1500 cells\/\u03bcL at 3 or 6 months after dupilumab administration is investigated. Results: A total of 37 individual were enrolled (male\/female = 14\/23, median age = 57.0 years old). The development of EGPA was significantly more frequent in the rising group compared with the peaked and declined group (p = 0.042, effect size = 0.455, moderate association). Patients with PBE counts greater than 1500 cells\/\u03bcL showed a significantly higher risk of developing EGPA (p = 0.017, effect size = 0.678, strong association). Conclusions: Physicians should check for the onset of EGPA by monitoring the elevation of eosinophils within 6 months after dupilumab administration, especially in patients with PBE counts greater than 1500 cells\/\u03bcL at 3 months.<\/jats:p>","DOI":"10.3390\/jcm12175721","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:12:22Z","timestamp":1693559542000},"page":"5721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Changes in Peripheral Blood Eosinophil Counts and Risk of Eosinophilic Granulomatosis with Polyangiitis Onset after Initiation of Dupilumab Administration in Adult Patients with Asthma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2571-2358","authenticated-orcid":false,"given":"Yoshitomo","family":"Kushima","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-7739","authenticated-orcid":false,"given":"Yasuo","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5288-5750","authenticated-orcid":false,"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meitetsu","family":"Masawa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okutomi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Yazawa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Chibana","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Dokkyo Medical University Nikko Medical Center, Nikko City 321-2335, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0049-7964","authenticated-orcid":false,"given":"Akihiro","family":"Takemasa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","article-title":"Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes","volume":"203","author":"Wenzel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: A Review of Present Indications and Off-Label Uses","volume":"32","author":"Moreno","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1121237","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Giunta, G., Pirola, F., Giombi, F., Muci, G., Pace, G.M., Heffler, E., Paoletti, G., Puggioni, F., Cerasuolo, M., and Ferreli, F. (2023). Care for Patients with Type-2 Chronic Rhinosinusitis. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040618"},{"key":"ref_5","unstructured":"(2023, July 14). ClinicalTrials.gov, Available online: https:\/\/beta.clinicaltrials.gov\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"627776","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic Granulomatosis with Polyangiitis: Dissecting the Pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients with Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","unstructured":"Pagana, P.T., and Pagana, T.J. (2020). Mosby\u2019s\u00ae Diagnostic and Laboratory Test Reference, Elsevier eBook on VitalSource. [15th ed.]."},{"key":"ref_15","first-page":"301","article-title":"Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease","volume":"16","author":"Celli","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1513\/AnnalsATS.202010-1249OC","article-title":"A Comprehensive Analysis of the Stability of Blood Eosinophil Levels","volume":"18","author":"Chipps","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5114\/ada.2020.95954","article-title":"Vascular endothelial growth factor-activated basophils in asthmatics","volume":"37","author":"Liebhart","year":"2020","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5114\/ada.2021.103498","article-title":"Peripheral blood eosinophils priming and in vitro vascular endothelial growth factor stimulation in asthmatics","volume":"38","author":"Liebhart","year":"2021","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/lary.30422","article-title":"Outcomes of Non-Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience","volume":"133","author":"Pirola","year":"2023","journal-title":"Laryngoscope"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pirola, F., Giunta, G., Muci, G., Giombi, F., Nappi, E., Grizzi, F., Heffler, E., Paoletti, G., Canonica, G.W., and Mercante, G. (2023). Evolution in Endoscopic Sinus Surgery: The Adjuvant Role of Reboot Surgery in Patients with Uncontrolled Nasal Symptoms of Eosinophilic Granulomatosis with Polyangiitis. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040647"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/alr.23049","article-title":"Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis","volume":"12","author":"Giombi","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_24","unstructured":"Asthma, G.I.f. (2022, November 01). Global Strategy for Asthma Management and Prevention (Updated 2018). Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/01\/2018-GINA.pdf."},{"key":"ref_25","first-page":"103","article-title":"Measurement of Fractional Exhaled Nitric Oxide with a Stationary Analyzer (NOA280i\u00ae) or Hand-held Analyzer (NIOX MINO\u00ae) Shows a Strong Correlation but Weaker Correlation at Higher Levels","volume":"46","author":"Ryo","year":"2019","journal-title":"Dokkyo J. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.21037\/jtd-19-3913","article-title":"Real-life effectiveness of fluticasone furoate\/vilanterol after switching from fluticasone\/salmeterol or budesonide\/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study)","volume":"12","author":"Shimizu","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 Guideline on Management of Vasculitis Syndrome\u2014Digest Version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia Induced by Blocking the IL-4\/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_31","first-page":"e25218","article-title":"Exacerbation of Eosinophilic Granulomatosis with Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis with Nasal Polyposis","volume":"14","author":"Tanaka","year":"2022","journal-title":"Cureus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11882-022-01039-w","article-title":"The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): An Illustrative Case and Discussion","volume":"22","author":"Milne","year":"2022","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_33","first-page":"e27670","article-title":"Dupilumab-Associated Eosinophilic Granulomatosis with Polyangiitis","volume":"14","author":"Persaud","year":"2022","journal-title":"Cureus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2169\/internalmedicine.7990-21","article-title":"Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab","volume":"61","author":"Ikeda","year":"2022","journal-title":"Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Suzaki, I., Tanaka, A., Yanai, R., Maruyama, Y., Kamimura, S., Hirano, K., and Kobayashi, H. (2023). Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: A case report. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02415-6"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_39","first-page":"100821","article-title":"Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma","volume":"79","author":"Descamps","year":"2021","journal-title":"Respir. Med. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:00Z","timestamp":1760129100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175721"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175721","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}